Deep Longevity’s new US telehealth platform, Accrua, ties treatment plans to a blood-based aging score and re-tests every ...

The Austin-based microbiome testing company raised a $33M Series B, and adults now outnumber babies in its testing volume.

First-in-human ER-100 data support dose escalation, with early visual-field signals in two of three glaucoma patients.

The Parkinson’s enzyme therapy is still heading toward the clinic, and the deal could grow by up to $1.17bn in milestone ...

New Singapore masterclass will give senior leaders three days to turn geroscience, personal data and market evidence into strategy. The science gets about 20% of the timetable. That is enough to ...

Pharma has the podium as Novo and Lilly stop talking about GLP-1 longevity and start measuring it, bringing early aging data ...

At ARDD 2026, senior FDA officials sketch how a therapy targeting aging might one day reach approval, revealing that ...

Designerly’s Cooper Adwin looks at why generative AI Is re-engineering skin rejuvenation and phasing out animal collagen. The global skin longevity industry runs on collagen that it cannot reliably ...

Novartis’ President of Biomedical Research, Fiona Marshall, on what it would take for big pharma to go all in on longevity. When the person who runs research for one of the world’s largest drug ...

Aged beagle data hint at lower biological age and preliminary muscle changes with SIRT6c treatment, although key readouts ...

A five-year NIA grant puts UCLA Health in charge of checking whether AI tools for Alzheimer’s care work before they spread. The program goes by APEX-ADRD, short for Accelerating Platforms for ...